Display options
Cite
Olawaiye AB, Java JJ, Krivak TC, et al. Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23]. Gynecol Oncol. 2018;152(1):220doi: 10.1016/j.ygyno.2018.10.022.
Olawaiye, A. B., Java, J. J., Krivak, T. C., Friedlander, M., Mutch, D. G., Glaser, G., Geller, M., O'Malley, D. M., Wenham, R. M., Lee, R. B., Bodurka, D. C., Herzog, T. J., & Bookman, M. A. (2019). Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23]. Gynecologic oncology, 152(1), 220. https://doi.org/10.1016/j.ygyno.2018.10.022
Olawaiye, Alexander B, et al. "Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23]." Gynecologic oncology vol. 152,1 (2019): 220. doi: https://doi.org/10.1016/j.ygyno.2018.10.022
Olawaiye AB, Java JJ, Krivak TC, Friedlander M, Mutch DG, Glaser G, Geller M, O'Malley DM, Wenham RM, Lee RB, Bodurka DC, Herzog TJ, Bookman MA. Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23]. Gynecol Oncol. 2019 Jan;152(1):220. doi: 10.1016/j.ygyno.2018.10.022. Epub 2018 Oct 23. PMID: 30360899; PMCID: PMC6321790.
Copy Download .nbib Format: NLM
Share it on

Gynecol Oncol. 2019 Jan;152(1):220. doi: 10.1016/j.ygyno.2018.10.022. Epub 2018 Oct 23.

Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23].

Gynecologic oncology

Alexander B Olawaiye, James J Java, Thomas C Krivak, Michael Friedlander, David G Mutch, Gretchen Glaser, Melissa Geller, David M O'Malley, Robert M Wenham, Roger B Lee, Diane C Bodurka, Thomas J Herzog, Michael A Bookman

Affiliations

  1. Division of Gynecologic Oncology, Magee-Womens Hospital of UPMC, Pittsburgh, PA, United States of America. Electronic address: [email protected].
  2. NRG Oncology, Clinical Trial Development Division, Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, United States of America.
  3. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Western Pennsylvania Hospital, Pittsburgh, PA, United States of America.
  4. Prince of Wales Clinical School UNSW, Department of Medical Oncology, The Prince of Wales Hospital, Sydney, Australia.
  5. Dept. of Obstetrics and Gynecology, Washington University School of Medicine, Saint Louis, MO 63110, United States of America.
  6. Gynecologic Oncology, Carilion Clinic Gynecological Oncology, Roanoke, VA 24016, United States of America.
  7. Dept. of Obstetrics, Gynecology and Women's Health, University of Minnesota Medical Center-Fairview, Minneapolis, MN 55455, United States of America.
  8. Dept. of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, United States of America.
  9. Department of Gynecologic Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, United States of America.
  10. Tacoma General Hospital, Tacoma,WA, United States of America.
  11. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States of America.
  12. Dept. of Obstetrics & Gynecology, University of Cincinnati Cancer Institute, University of Cincinnati, Cincinnati, OH 45267, United States of America.
  13. The Permanente Medical Group, Inc., 2350 Geary Blvd, Room 115, San Francisco, CA 94115, United States of America.

PMID: 30360899 PMCID: PMC6321790 DOI: 10.1016/j.ygyno.2018.10.022

[No abstract available.]

Publication Types

Grant support